Eileen M. O'Reilly, MD
Gastrointestinal Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Winthrop Rockefeller Endowed Chair of Medical Oncology
- Chair, Human Research Protection Program and Institutional Review Board
- Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research
- Section Head, Hepatopancreaticobi
I am a medical oncologist who cares for people with pancreatic and hepatobiliary (hep-uh-toh-BIL-ee-air-ee) cancers, including:
- Pancreatic cancer
- Liver cancer
- Bile duct cancer (cholangiocarcinoma)
- Gallbladder cancer
- Other gastrointestinal cancers
At Memorial Sloan Kettering Cancer Center (MSK), I work closely with a team of experts across medical areas. These include:
- Surgery
- Medical oncology
- Gastroenterology
- Radiation oncology
- Integrative medicine
- Social work
Together, we create a care plan that best treats each person’s cancer while honoring their personal wants and needs for cancer treatment. To achieve these goals, I communicate clearly and effectively with every patient, their family, and other team members. I strive for excellence in these areas as part of my commitment to offer the best possible care.
Read more
My research focuses on developing new therapies for pancreatic cancer, such as:
- Gene-based treatments.
- Immunotherapy (including vaccines).
- Personalized treatments that target a cancer’s unique molecular makeup.
I also lead many clinical trials for people with this disease. Our hope is that this work leads to approved treatments that help people with pancreatic cancer live longer and have a better quality of life.
I co-direct a major federally-funded grant called the Specialized Program in Research Excellence (SPORE) for pancreatic cancer. This grant supports investigators using the latest molecular biology and clinical advances to improve care for people with pancreatic ductal adenocarcinoma (PDAC).
I have authored and co-authored more than 400 articles, editorials, and book chapters. I also serve as Associate/Senior Editor for several major journals.
In addition to caring for patients and leading research, I am Chair of MSK’s Human Research Protection Program and the Institutional Review and Privacy Board. In this role, I work closely with a team of people to oversee how research is conducted at MSK.
Education is another important part of my work. I teach and mentor national and international oncology fellows, junior faculty, residents, house staff, and students. It’s an honor to have been recognized with many teaching awards for these efforts.
Outside of MSK, I work with groups and experts around the world to improve care for people with pancreas and hepatobiliary cancers. I am Co-Chair of the National Cancer Institute (NCI) Alliance Co-Operative Group Gastrointestinal Cancers Committee and a member of the NCI’s Gastrointestinal Cancers Steering Committee. These committees are involved in developing and overseeing federally-funded clinical trials in gastrointestinal cancers.
I also serve on the medical and/or scientific advisory board of various organizations and other national/international committees including:
- Pancreatic Cancer Action Network
- American Society of Clinical Oncology Guidelines Committee
- European Society of Medical Oncology Guidelines Committee
- National Pancreas Foundation
- Hirshberg Foundation
- Avner Foundation
In my spare time, I enjoy being with my family, reading, classical music, traveling to Europe and Asia, cultivating plants, and watching films.
A gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
My Specialties
- Pancreatic Cancer
- Gallbladder Cancer
- Bile Duct Cancer
- Primary Liver Cancer
- Gastrointestinal Neuroendocrine Cancers
Education
- MD, Trinity College, Ireland
Residencies
- Internal Medicine - St. James's Hospital
Awards and Honors
- Castle Connolly: Exceptional Women in Medicine (2024)
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Giant of Cancer Care, Gastrointestinal Cancer, OncLive (2023)
- Exceptional Women in Medicine Award, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2005-2023)
- Burkitt Medal (TCD)
Fellowships
- Internal Medicine/Medical Oncology - St. Vincent's Hospital (Ireland)
- Medical Oncology - Memorial Sloan Kettering Cancer Center
- Medicine - Cornell University Medical Center
Board Certifications
- Internal Medicine (Ireland)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. O'Reilly sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. O'Reilly
- A Phase 1 Study of ELI-002 7P Immunotherapy in People with Digestive Cancers
- A Phase 1b Study of AMG 193 Plus mFOLFIRINOX or With Gemcitabine and Nab-paclitaxel in People With Advanced Pancreatic Cancer
- A Phase 2 Study of Nab-paclitaxel and Gemcitabine With or Without Botensilimab in People With Advanced Pancreatic Cancer
- A Phase I Study of AB680 in Combination with AB122 Immunotherapy, Nab-Paclitaxel, and Gemcitabine in People with Advanced Pancreatic Cancer
Read more
- A Phase I Study of MVT-5873 Alone or with Chemotherapy in Patients with Pancreatic Cancer and Other CA19-9 Positive Tumors
- A Phase I Study to Evaluate Different Immunotherapy and Chemotherapy Combinations for Previously Untreated Metastatic Pancreatic Cancer
- A Phase IB/II Study Assessing Multiple Immunotherapy Treatments in Patients with Metastatic Pancreatic Cancer
- A Study of Pancrelipase Enzyme Replacement Therapy in People with Advanced Pancreatic Cancer
- Clinical Trials Co-Investigated by Dr. O'Reilly
- A Phase 1 Study of ASP2138 in People With Pancreatic Cancer or Stomach or Gastroesophageal Junction Cancer That Makes Claudin (CLDN) 18.2
- A Phase 1/2 Study of AMG 193 Plus IDE397 to Treat Advanced Digestive Cancers Lacking the MTAP Protein
- A Phase 1/2 Study of Gemcitabine and Nab-paclitaxel Plus Avutometinib and Defactinib in People With Advanced Pancreatic Cancer
- A Phase 2 Study of an mRNA Vaccine plus Immunotherapy and Chemotherapy Versus Chemotherapy Alone for People with Operable Pancreatic Cancer
- A Phase 2 Study of NALIRIFOX Plus Radiation Therapy to Treat Pancreatic Cancer
- A Phase I Study of ASP3082 in People with Solid Tumors with KRAS G12D Mutations
- A Phase II Study of Olaparib in Patients with Advanced Biliary Tract Cancer
- A Phase II Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation
- A Phase II/III Study Comparing Different Therapies for Metastatic Pancreatic Cancer
- A Phase III Study of Chemotherapy After Surgery versus Chemotherapy Before and After Surgery for Operable Pancreatic Cancer
- A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. O'Reilly’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Eileen M. O'Reilly discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities (Uncompensated) -
Alligator Bioscience AB
Professional Services and Activities -
American Society of Clinical Oncology (ASCO)
Professional Services and Activities -
AstraZeneca
Professional Services and Activities (Uncompensated) -
AUTEM Medical, LLC
Professional Services and Activities (Uncompensated) -
Boehringer Ingelheim
Professional Services and Activities (Uncompensated) -
Bristol-Myers Squibb
Professional Services and Activities -
General Electric
Professional Services and Activities -
HMP Oncology Learning Network
Professional Services and Activities -
Hookipa Biotech
Professional Services and Activities
-
Imedex, Inc.
Professional Services and Activities -
Ipsen
Professional Services and Activities (Uncompensated) -
Leap Therapeutics Inc.
Professional Services and Activities (Uncompensated) -
Merck & Co Inc.
Professional Services and Activities (Uncompensated) -
Merus
Professional Services and Activities -
Neogene Therapeutics Inc
Professional Services and Activities (Uncompensated) -
Novartis
Professional Services and Activities -
Research to Practice
Professional Services and Activities -
Revolution Medicines
Professional Services and Activities (Uncompensated) -
Syros Pharmaceuticals, Inc.
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].